3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Hematologic Neoplasms
4
Urinary Bladder Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Salivary Gland Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Multiple Myeloma
1
Melanoma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Leukemia
1
Glioma
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Interventions
fludarabine
6
Tacrolimus
6
Busulfan
6
blinatumomab
5
Rituximab
5
Cyclophosphamide
5
fludarabine phosphate
4
Peripheral Blood Stem Cell Transplantation
4
Mycophenolic Acid
4
Epoetin Alfa
4
venetoclax
3
Whole-Body Irradiation
3
Methotrexate
3
Darbepoetin alfa
3
Alemtuzumab
3
ponatinib
2
ibrutinib
2
entrectinib
2
alectinib
2
Thiotepa
2
Therapeutics
2
Patient Reported Outcome Measures
2
Mesna
2
Melphalan
2
Everolimus
2
Early Intervention, Educational
2
Bone Marrow Transplantation
2
Antilymphocyte Serum
2
vandetanib
1
trametinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoproliferative Disorders
×
Trastuzumab
×
Other hematologic neoplasm
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled